Evidence map›Paper›PMID 38928138›Full record

Trial reportInternational journal of molecular sciences2024

Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries.

Anja Seckinger, Hans Salwender, Hans Martin, Christof Scheid, Thomas Hielscher, Uta Bertsch, Manuela Hummel, Anna Jauch, Wolfgang Knauf, Martina Emde-Rajaratnam and 13 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Anja SeckingerDepartment of Hematology and Immunology, Myeloma Center Brussels & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), 1090 Jette, Belgium.ORCID 0000-0002-2771-712X
Hans SalwenderDepartment of Internal Medicine II, Asklepios Klinik Altona, 22763 Hamburg, Germany.
Hans MartinDepartment of Medicine, Hematology/Oncology, Goethe-University of Frankfurt, 60590 Frankfurt, Germany.
Christof ScheidDepartment I of Internal Medicine, University of Cologne, 50923 Köln, Germany.ORCID 0009-0007-6539-226X
Thomas HielscherAbteilung für Biostatistik, Deutsches Krebsforschungszentrum, 69120 Heidelberg, Germany.ORCID 0000-0003-1277-310X
Uta BertschMedizinische Klinik V, Universitätsklinikum Heidelberg, 69120 Heidelberg, Germany.ORCID 0000-0001-5584-3951
Manuela HummelAbteilung für Biostatistik, Deutsches Krebsforschungszentrum, 69120 Heidelberg, Germany.
Anna JauchInstitut für Humangenetik, Universität Heidelberg, 69120 Heidelberg, Germany.
Wolfgang KnaufOnkologische Gemeinschaftspraxis, Agaplesion Bethanien Krankenhaus, 60389 Frankfurt, Germany.
Martina Emde-RajaratnamDepartment of Hematology and Immunology, Myeloma Center Brussels & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), 1090 Jette, Belgium.
Susanne BeckDepartment of Hematology and Immunology, Myeloma Center Brussels & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), 1090 Jette, Belgium.
Kai NebenKlinikum Mittelbaden, Medizinische Klinik 2, 76530 Baden-Baden, Germany.ORCID 0000-0003-1311-8107
Jan DührigKatholisches Krankenhaus Hagen, 58099 Hagen, Germany.
Walter LindemannDepartment of Hematology, University Hospital Essen, 45147 Essen, Germany.
Ingo G H Schmidt-WolfDepartment of Integrated Oncology, CIO Bonn, University of Bonn, 53127 Bonn, Germany.ORCID 0000-0002-5655-0867
Mathias HänelDepartment of Internal Medicine III, Klinikum Chemnitz GmbH, 09113 Chemnitz, Germany.
Igor W BlauMedical Clinic III Hematology and Oncology, Charité University Medicine Berlin, 13353 Berlin, Germany.
Katja WeiselDepartment of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Niels WeinholdMedizinische Klinik V, Universitätsklinikum Heidelberg, 69120 Heidelberg, Germany.
Marc S RaabMedizinische Klinik V, Universitätsklinikum Heidelberg, 69120 Heidelberg, Germany.
Hartmut GoldschmidtMedizinische Klinik V, Universitätsklinikum Heidelberg, 69120 Heidelberg, Germany.ORCID 0000-0003-0961-0035
Mimi Choon-QuinonesIndependent Myeloma Alliance, 8808 Pfäffikon, SZ, Switzerland.
Dirk HoseDepartment of Hematology and Immunology, Myeloma Center Brussels & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), 1090 Jette, Belgium.

Funding

Deutsche Forschungsgemeinschaft SFB/TRR79)German Federal Ministry of Education 01ES1103 and 01ZX1309
6 · The paper itself

Abstract

Based on the lack of differences in progression-free and overall survival after a median follow-up of 93 months in our HOVON-65/GMMG-HD4 trial (German part;

Indexed as

Chromosome AberrationsMultiple MyelomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBortezomibCell ProliferationDeveloping CountriesDexamethasoneFemaleHumansMaleMiddle AgedPrognosisThalidomideBortezomibDexamethasoneThalidomideLMICmolecular profilingmultiple myelomaproliferationresponsesurvival

Identifiers

PMID38928138
PMCPMC11204152

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.